Sophisticated computer models are learning how to treat lung disorders, linking up the underlying problem with the right treatment.
Asthma affects 300 million people worldwide and causes 239 000 deaths, while 80 million have moderate-to-severe chronic obstructive pulmonary disease (COPD). And the numbers are rising.
The difficulty with current treatment is that two people may have similar breathing trouble but, because the fundamental cause of their problem is different, giving them the same medication can lead to a good result for one of the patients but no improvement in the other.
‘The way we define disease is still based on their symptoms, but we are learning that underlying the things patients complain about is quite a broad spectrum of biological processes,’ said Professor Chris Brightling of the University of Leicester, UK, who leads the EU-funded AirPROM research consortium.
He hopes the ‘one-size-fits-all’ approach to managing asthma and COPD may become a thing of the past.
‘We are learning that underlying the things patients complain about is quite a broad spectrum of biological processes.’
Prof. Chris Brightling, leader of the AirPROM project
‘Recognising this diversity is important if we are to give the right treatment to the right patient and this approach may also guide drug discovery,’ said Prof. Brightling.
AirPROM brings together a diverse group of experts to develop sophisticated models that can predict how an individual’s lung disease will progress and how they will respond to various treatment options.
Scientists at AirPROM are using data from people with asthma or COPD who previously took part in other EU-funded studies such as BTS Severe Asthma, U-BIOPRED and EvA FP7.
This provides a wealth of information from lung function tests, blood samples, cells from the lung, and images from CT and MRI scans.
‘We have models for different parts of the disease. Some treatments may be targeting very specific pathways at a cellular or even subcellular level. Others may be affecting the airway more directly,’ said Prof. Brightling.
The more patient data that is added to the system, the more the computer models ‘learn’, becoming more accurate in treating the individual patient.
At the Clinical Investigation Centre in Laennec hospital, Nantes, an asthmatic patient exhales into a devise to measure the content of nitric oxide in their breath.© INSERM/ Patrice Latron
This personalised approach could pave the way for patients to have a series of tests – lung function, blood samples, MRI scans – when they see their doctor. That means their treatment is tailored to their specific disease, making it much more likely to deliver results.
The cost of this modelling is not yet clear but could be in the order of EUR 5 000 per patient, particularly where CT or MRI scans are used. This suggests it may not be used for every patient with mild asthmatic symptoms, but could help to guide doctors’ decisions when prescribing expensive biological treatments or surgical interventions to those with more serious conditions.
‘Some of the newer biologics might cost EUR 20 000 to EUR 30 000 per patient per year while thermoplasty (using radio waves to apply heat to the lungs) could be EUR 10 000. So it may still be cheaper to do the modelling if we can predict which patients will do well, which will do badly, and even which ones are at risk of potential harm,’ said Prof. Brightling.
A research group is looking at the mechanisms through which rhinoviruses – which cause the common cold – trigger acute bouts of lung disease in people with asthma.
‘We find that people with asthma and people without asthma get colds – but people with asthma suffer more rapid onset, more severe symptoms and the illness is longer-lasting,’ said Professor Sebastian Johnston who works on the EU-funded MORIAE project.
His team has developed an inhaled medication which is being tested in asthma patients to help spur the body’s defence mechanism. If it is proven to work, the idea would be for asthma patients to take it when they feel a cold coming on. This could, it is hoped, prevent or control the worst of virus-induced asthma attacks.
Nearly 100 years ago scientists developed a vaccine for tuberculosis (TB). Today, there are 10 million new cases worldwide and 1.6 million deaths from the disease every year. Increasingly, these cases are becoming difficult to treat as the bug that causes the disease can be resistant to antibiotics. However, several new TB vaccines are under development and there is growing optimism that a new vaccine will emerge, says Helen McShane, professor of vaccinology at Oxford University, UK. This could save millions of lives, she said, but more work is needed to reassure the general public that vaccines are safe and effective.
Few technologies have the potential to disrupt old institutions as much as blockchain – a system that maintains records on huge networks of individual computers. As with any new technology, it could be used for social good – such as supporting people who are priced-out of the current bank accounts – but the big challenge is how to limit its unintended consequences.
Forests have a special magic for many of us. Steeped in folklore and fantasy, they are places for enchantments, mythical creatures and outlaws. But if they are to survive into the future, they may also need a helping hand from science.
Nature provides people with everything from food and water to timber, textiles, medicinal resources and pollination of crops. Now, a new approach aims to measure exactly what a specific ecosystem supplies in order to incentivise decision-makers and businesses to help combat biodiversity loss.
Tuberculosis is the most common cause of death from an infectious disease.
Computer modelling will also help optimise management techniques.
Entrepreneur Nicklas Bergman on the European Innovation Council.